Headache and Migraine

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the potential of INP104 to improve migraine patient care.

The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine

Here's what is coming soon to NeurologyLive.

The director of the Headache Center of Southern California shared his thoughts on the factors and barriers that go into conducting trials that treat patients with migraine with multiple drugs.

Neurology News Network for the week ending June 12, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

The medical director of the Westport Headache Institute shared her insight into the use of the e-TNS device and the role of neuromodulation in migraine.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why advanced practice clinicians should be utilized more in neurology settings.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.

The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

A post-hoc analysis of the phase 2/3 trial of rimegepant revealed early and sustained efficacy compared to placebo, with significant reductions in weekly migraine days.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the advantages of INP104 over other forms of dihydroergotamine.

Investigators conducted a 9-month study that demonstrated the correlation of the MBI, calculated as the sum of headache days times the maximum intensity of headache on each headache day, with satisfaction of migraine status.

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.

A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.

The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.

These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.

The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.

Here's what is coming soon to NeurologyLive.

An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.

The director of the Headache Center of Southern California discussed his research from AHS 2021 which evaluated safety and efficacy of combined treatment with CGRPs and onabotulimtoxinA.